AI Analysis
AI-generated analysis. Always verify with the original filing.
Revenue exploded 957% to $1.1M from the Evoke Neuroscience acquisition, driving gross profit to $645K at 56.5% margins, while operating loss improved 12% to -$8.9M through post-rebranding cost discipline, though net loss widened to -$19.9M on non-operating charges.
Key Takeaways
1Revenue surged 957% to $1.1M from $108K, primarily due to revenue from the acquisition of Evoke Neuroscience, marking the first meaningful scale-up in commercialization.
2Operating loss narrowed 12% to -$8.9M from -$10.1M, reflecting reduced consultant use following 2024 rebranding efforts.
3Net loss expanded 90% to -$19.9M from -$10.5M, with diluted EPS worsening 23% to -$1.97, driven by non-operating items beyond core operations.
4Net cash used in operating activities increased to -$8.2M from -$6.2M due to higher day-to-day costs, liability reductions, and R&D for BNA and Evoke integrations.